S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

Compare Stocks

Date Range: 

 NovartisMerck & Co., Inc.AstraZenecaAbbVieAbbott Laboratories
SymbolNYSE:NVSNYSE:MRKNASDAQ:AZNNYSE:ABBVNYSE:ABT
Price Information
Current Price$82.73$81.54$61.77$108.40$127.71
50-Day Moving Average$87.19$76.72$58.67$111.59$123.28
52-Week Low$77.04$70.89$46.48$79.11$103.13
52-Week High$98.52$85.60$62.69$121.53$129.70
MarketRank™
Overall Score2.23.02.73.62.9
Analysis Score3.13.44.43.52.4
Community Score4.34.55.04.94.8
Dividend Score2.54.22.55.04.2
Ownership Score0.01.70.02.52.5
Earnings & Valuation Score1.31.31.91.90.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$108.50$93.42$124.00$126.67$136.57
% Upside from Price Target31.15% upside14.57% upside100.74% upside16.86% upside6.94% upside
Trade Information
Market Cap$185.05 billion$206.41 billion$191.38 billion$191.56 billion$226.41 billion
Beta0.540.410.530.820.66
Average Volume1,925,33312,257,6049,299,6176,936,5355,371,196
Sales & Book Value
Annual Revenue$48.66 billion$47.99 billion$26.62 billion$45.80 billion$34.61 billion
Price / Sales3.804.307.194.186.54
Cashflow$8.16 per share$8.21 per share$3.52 per share$13.95 per share$5.53 per share
Price / Cash10.149.9317.547.7723.11
Book Value$24.76 per share$10.04 per share$5.96 per share$7.42 per share$18.62 per share
Price / Book3.348.1210.3614.616.86
Profitability
Net Income$8.07 billion$7.07 billion$3.20 billion$4.62 billion$4.50 billion
EPS$5.75$5.94$2.01$10.56$3.65
Trailing P/E Ratio20.9437.2342.9029.2235.97
Forward P/E Ratio12.3712.9817.457.8027.41
P/E Growth2.072.161.212.012.45
Net Margins17.83%11.48%12.77%12.40%15.85%
Return on Equity (ROE)25.25%50.93%40.02%154.24%26.75%
Return on Assets (ROA)10.74%16.15%8.82%14.10%12.31%
Dividend
Annual Payout$2.08$2.60$1.37$5.20$1.80
Dividend Yield2.51%3.19%2.22%4.80%1.41%
Three-Year Dividend Growth13.60%31.22%N/A84.37%35.85%
Payout Ratio36.17%43.77%68.16%49.24%49.32%
Years of Consecutive Dividend Growth2 Years10 YearsN/A49 Years49 Years
Debt
Debt-to-Equity Ratio0.460.721.545.890.52
Current Ratio0.801.311.230.911.79
Quick Ratio0.561.061.010.791.36
Ownership Information
Institutional Ownership Percentage9.90%71.83%13.88%65.82%72.05%
Insider Ownership Percentage0.01%0.32%N/A0.09%1.50%
Miscellaneous
Employees105,79473,50076,1002,020109,000
Shares Outstanding2.24 billion2.53 billion3.10 billion1.77 billion1.77 billion
Next Earnings Date1/25/2022 (Estimated)10/28/2021 (Confirmed)11/12/2021 (Confirmed)10/29/2021 (Confirmed)1/26/2022 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Philip P. Boudreau Sells 8,000 Shares of Abbott Laboratories (NYSE:ABT) StockPhilip P. Boudreau Sells 8,000 Shares of Abbott Laboratories (NYSE:ABT) Stock
americanbankingnews.com - October 27 at 8:08 PM
Earnings Estimates Rising for Abbott (ABT): Will It Gain?Earnings Estimates Rising for Abbott (ABT): Will It Gain?
finance.yahoo.com - October 27 at 6:43 PM
Abbott Named One the 100 Best ESG Companies by Investors Business DailyAbbott Named One the 100 Best ESG Companies by Investor's Business Daily
finance.yahoo.com - October 27 at 6:43 PM
Wednesdays Top Analyst Upgrades and Downgrades: Abbott Labs, Alphabet, Cloudflare, DraftKings, Microsoft, UPS and MoreWednesday's Top Analyst Upgrades and Downgrades: Abbott Labs, Alphabet, Cloudflare, DraftKings, Microsoft, UPS and More
247wallst.com - October 27 at 1:42 PM
Not A Good News For Abbott Laboratories (NYSE: ABT): Stock Could Even Fall -14.04%Not A Good News For Abbott Laboratories (NYSE: ABT): Stock Could Even Fall -14.04%
stocksregister.com - October 27 at 1:42 PM
Masimos (MASI) Q3 Earnings Surpass Estimates, 21 View UpMasimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
finance.yahoo.com - October 27 at 1:42 PM
In Q3 earnings, Boston Scientific acknowledges Covid-19 headwindsIn Q3 earnings, Boston Scientific acknowledges Covid-19 headwinds
finance.yahoo.com - October 27 at 1:42 PM
Abbott Laboratories (NYSE:ABT) Stock Rating Upgraded by Atlantic SecuritiesAbbott Laboratories (NYSE:ABT) Stock Rating Upgraded by Atlantic Securities
americanbankingnews.com - October 27 at 10:11 AM
Abbott Laboratories (NYSE: ABT) Prices Could Soar To Much Higher Levels In Coming MonthsAbbott Laboratories (NYSE: ABT) Prices Could Soar To Much Higher Levels In Coming Months
marketingsentinel.com - October 27 at 8:42 AM
Abbott Laboratories (NYSE:ABT) Raised to "Overweight" at Atlantic SecuritiesAbbott Laboratories (NYSE:ABT) Raised to "Overweight" at Atlantic Securities
marketbeat.com - October 27 at 7:18 AM
Analysts say Boston Scientific faces higher level of exposure to riskAnalysts say Boston Scientific faces 'higher level of exposure' to risk
finance.yahoo.com - October 26 at 5:15 AM
Redburn lifts Abbott Laboratories [ABT] price estimate. Who else is bullish?Redburn lifts Abbott Laboratories [ABT] price estimate. Who else is bullish?
dbtnews.com - October 25 at 10:57 PM
Global DNA Sequencing Market worth $24,257.75 million by 2027| CAGR 18.61% : Qualiket ResearchGlobal DNA Sequencing Market worth $24,257.75 million by 2027| CAGR 18.61% : Qualiket Research
benzinga.com - October 25 at 1:25 PM
Podcast: How to Turn STEM Curiosity Into a CareerPodcast: How to Turn STEM Curiosity Into a Career
finance.yahoo.com - October 25 at 12:56 PM
William Blair Analysts Increase Earnings Estimates for Abbott Laboratories (NYSE:ABT)William Blair Analysts Increase Earnings Estimates for Abbott Laboratories (NYSE:ABT)
americanbankingnews.com - October 25 at 2:26 AM
SVB Leerink Analysts Lift Earnings Estimates for Abbott Laboratories (NYSE:ABT)SVB Leerink Analysts Lift Earnings Estimates for Abbott Laboratories (NYSE:ABT)
americanbankingnews.com - October 25 at 2:26 AM
Abbott Laboratories (NYSE:ABT) Expected to Post Q4 2021 Earnings of $1.12 Per ShareAbbott Laboratories (NYSE:ABT) Expected to Post Q4 2021 Earnings of $1.12 Per Share
americanbankingnews.com - October 22 at 9:48 AM
Q4 2021 EPS Estimates for Abbott Laboratories Lifted by Analyst (NYSE:ABT)Q4 2021 EPS Estimates for Abbott Laboratories Lifted by Analyst (NYSE:ABT)
americanbankingnews.com - October 22 at 9:14 AM
Abbott Laboratories (NYSE:ABT) Shares Rebounded 17.07% From Their Lows – But Can They Continue?Abbott Laboratories (NYSE:ABT) Shares Rebounded 17.07% From Their Lows – But Can They Continue?
marketingsentinel.com - October 21 at 6:47 PM
Abbott Laboratories (NYSE:ABT) PT Raised to $134.00 at Raymond JamesAbbott Laboratories (NYSE:ABT) PT Raised to $134.00 at Raymond James
americanbankingnews.com - October 21 at 10:40 AM
Abbott Laboratories (NYSE:ABT) PT Raised to $140.00Abbott Laboratories (NYSE:ABT) PT Raised to $140.00
americanbankingnews.com - October 21 at 10:40 AM
Morgan Stanley Raises Abbott Laboratories (NYSE:ABT) Price Target to $146.00Morgan Stanley Raises Abbott Laboratories (NYSE:ABT) Price Target to $146.00
americanbankingnews.com - October 21 at 10:06 AM
Abbott Exceeds Q3 Expectations; Shares Jump 3.3%Abbott Exceeds Q3 Expectations; Shares Jump 3.3%
finance.yahoo.com - October 21 at 8:46 AM
3 Things Investors Should Love About Abbotts Q3 Results3 Things Investors Should Love About Abbott's Q3 Results
finance.yahoo.com - October 21 at 8:46 AM
Why Abbott Laboratories Shot Higher TodayWhy Abbott Laboratories Shot Higher Today
fool.com - October 20 at 4:50 PM
How major US stock indexes fared WednesdayHow major US stock indexes fared Wednesday
marketbeat.com - October 20 at 4:34 PM
Abbott Laboratories 2021 Q3 - Results - Earnings Call PresentationAbbott Laboratories 2021 Q3 - Results - Earnings Call Presentation
seekingalpha.com - October 20 at 3:45 PM
Stocks rise on Wall Street, S&P 500 hovers near record highStocks rise on Wall Street, S&P 500 hovers near record high
marketbeat.com - October 20 at 2:27 PM
Stocks rise on Wall Street, S&P 500 hovers around highStocks rise on Wall Street, S&P 500 hovers around high
marketbeat.com - October 20 at 1:15 PM
Stocks edge higher on Wall Street, led by health careStocks edge higher on Wall Street, led by health care
marketbeat.com - October 20 at 10:49 AM
Dividend Aristocrat Abbott Laboratories Is On Track For New HighsDividend Aristocrat Abbott Laboratories Is On Track For New Highs
marketbeat.com - October 20 at 10:30 AM
Cowen Reiterates "Buy" Rating for Abbott Laboratories (NYSE:ABT)Cowen Reiterates "Buy" Rating for Abbott Laboratories (NYSE:ABT)
marketbeat.com - October 9 at 12:08 PM
3 Dividend Aristocrat Stocks to Buy for Passive Income (ABT)3 Dividend Aristocrat Stocks to Buy for Passive Income (ABT)
marketbeat.com - September 8 at 7:30 PM
Abbott Labs Breaks Out Of Six-Month Base In Low TurnoverAbbott Labs Breaks Out Of Six-Month Base In Low Turnover
marketbeat.com - September 7 at 7:34 AM
Abbott Laboratories Proves Its Worth Again Abbott Laboratories Proves Its Worth Again 
marketbeat.com - July 22 at 9:19 AM
The Top 3 Healthcare Stocks to Buy in July (ABT)The Top 3 Healthcare Stocks to Buy in July (ABT)
marketbeat.com - July 6 at 7:23 PM
DateCompanyBrokerageAction
10/27/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
10/27/2021Abbott LaboratoriesAtlantic Securities
Upgrade
10/22/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
10/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
10/21/2021Abbott LaboratoriesSVB Leerink
Reiterated Rating
10/21/2021Abbott LaboratoriesRaymond James
Boost Price Target
10/19/2021AstraZenecaUBS Group
Reiterated Rating
10/14/2021Abbott LaboratoriesRedburn Partners
Initiated Coverage
10/12/2021NovartisBerenberg Bank
Reiterated Rating
10/12/2021Merck & Co., Inc.Morgan Stanley
Boost Price Target
10/11/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Reiterated Rating
10/10/2021Merck & Co., Inc.Berenberg Bank
Reiterated Rating
10/8/2021NovartisUBS Group
Reiterated Rating
10/8/2021Merck & Co., Inc.Barclays
Boost Price Target
10/8/2021Abbott LaboratoriesCowen
Reiterated Rating
10/4/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
10/1/2021Merck & Co., Inc.Mizuho
Initiated Coverage
10/1/2021Abbott LaboratoriesCitigroup
Boost Price Target
9/27/2021AstraZenecaSVB Leerink
Boost Price Target
9/20/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
9/20/2021AstraZenecaSVB Leerink
Boost Price Target
9/17/2021AstraZenecaMorgan Stanley
Reiterated Rating
9/7/2021Merck & Co., Inc.Morgan Stanley
Downgrade
9/2/2021AbbVieSVB Leerink
Lower Price Target
8/31/2021Abbott LaboratoriesBTIG Research
Boost Price Target
8/23/2021AbbVieCowen
Boost Price Target
8/23/2021Abbott LaboratoriesCowen
Boost Price Target
8/20/2021AbbVieMorgan Stanley
Reiterated Rating
8/20/2021AbbVieSVB Leerink
Boost Price Target
8/12/2021AstraZenecaJPMorgan Chase & Co.
Initiated Coverage
8/9/2021AstraZenecaMorgan Stanley
Initiated Coverage
8/5/2021AbbVieArgus
Boost Price Target
8/4/2021AstraZenecaSVB Leerink
Boost Price Target
8/2/2021AbbVieSVB Leerink
Boost Price Target
8/2/2021AbbVieMizuho
Boost Price Target
8/2/2021AbbVieBarclays
Boost Price Target
7/30/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
7/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
7/27/2021Merck & Co., Inc.Truist Securities
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist
Initiated Coverage
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/22/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
7/21/2021AstraZenecaCitigroup
Reiterated Rating
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/16/2021AstraZenecaSVB Leerink
Lower Price Target
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
6/17/2021AstraZenecaUBS Group
Reiterated Rating
6/9/2021Merck & Co., Inc.JPMorgan Chase & Co.
Lower Price Target
6/7/2021Merck & Co., Inc.Truist Securities
Lower Price Target
6/4/2021AstraZenecaSVB Leerink
Boost Price Target
6/3/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/20/2021Merck & Co., Inc.Argus
Reiterated Rating
5/11/2021NovartisMorgan Stanley
Reiterated Rating
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
4/28/2021NovartisOddo Bhf
Upgrade
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/19/2021NovartisUBS Group
Reiterated Rating
4/19/2021AstraZenecaArgus
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/12/2021AstraZenecaArgus
Downgrade
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/23/2021NovartisSociete Generale
Reiterated Rating
3/23/2021AstraZenecaSociete Generale
Reiterated Rating
3/22/2021NovartisSanford C. Bernstein
Initiated Coverage
3/18/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Reiterated Rating
3/16/2021NovartisArgus
Reiterated Rating
3/16/2021AstraZenecaJefferies Financial Group
Upgrade
3/10/2021NovartisArgus
Downgrade
3/9/2021AstraZenecaBerenberg Bank
Reiterated Rating
3/8/2021AstraZenecaBarclays
Reiterated Rating
3/2/2021AstraZenecaSVB Leerink
Lower Price Target
2/25/2021AstraZenecaUBS Group
Upgrade
2/5/2021Merck & Co., Inc.Cantor Fitzgerald
Reiterated Rating
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
2/2/2021NovartisMorgan Stanley
Reiterated Rating
2/1/2021NovartisCowen
Downgrade
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/22/2021NovartisBarclays
Reiterated Rating
1/22/2021AstraZenecaBarclays
Reiterated Rating
1/15/2021NovartisDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/15/2021AstraZenecaBerenberg Bank
Reiterated Rating
1/15/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/8/2021NovartisMorgan Stanley
Reiterated Rating
12/30/2020AstraZenecaAlphaValue
Upgrade
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
12/6/2020Merck & Co., Inc.Mizuho
Reiterated Rating
12/3/2020NovartisArgus
Boost Price Target
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/25/2020NovartisUBS Group
Reiterated Rating
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/10/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
11/10/2020Merck & Co., Inc.Sanford C. Bernstein
Reiterated Rating
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
10/29/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
10/23/2020Merck & Co., Inc.Truist
Initiated Coverage
10/16/2020Merck & Co., Inc.JPMorgan Chase & Co.
Boost Price Target
9/29/2020NovartisBerenberg Bank
Initiated Coverage
9/29/2020Merck & Co., Inc.Berenberg Bank
Initiated Coverage
9/23/2020NovartisOddo Bhf
Downgrade
9/22/2020Merck & Co., Inc.Mizuho
Reiterated Rating
9/10/2020NovartisUBS Group
Upgrade
8/25/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
8/4/2020Merck & Co., Inc.Royal Bank of Canada
Reiterated Rating
(Data available from 10/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.